Brown: Risk Weighti...
Health Care: Drugs
Repligen Corporation (RGEN: NASDAQ)
$8.85 -0.03 | -0.34%
05/17/13 - 04:00 PM ET
989.65K / 281.30K
Vol / Avg. Vol:8.94 / 8.88
Open / Prev. Close:8.75 - 9.10
Today's Range:3.72 - 9.65
52 Wk Range:41.40%
Performance YTD:TheStreet Rating:
Portfolios with RGEN
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- UserTrack1
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- Usersuperstocks
- ContributorStocks Under-$10 Moving Hig...
- UserGFNN Stockdiagnostics 9
- Userstarting out
Latest RGEN Headlines from TheStreet
- Repligen Reports First Quarter 2013 Financial Results 05.02.13 | 07:05 am
- Repligen To Report First Quarter 2013 Financial Results 04.23.13 | 05:04 pm
- Repligen Reports Fourth Quarter And Full Year 2012 Financial Results And Provides Financial Guidance For 2013 03.07.13 | 07:03 am
- Repligen To Report Fourth Quarter And Full Year 2012 Financial Results 03.01.13 | 01:03 pm
- 5 Stocks With Big Insider Buying 09.26.12 | 12:09 pm
- 5 Stocks Under $10 Set to Soar Higher 08.30.12 | 12:08 pm
- 5 Stocks Under $10 Set to Soar 08.16.12 | 01:08 pm
- 7 Stocks Under $10 Making Big Moves 08.02.12 | 02:08 pm
- 3 Stocks Under $5 Making Big Moves 06.14.12 | 01:06 pm
- Buy This Pharma With Double-Digit Growth Projections 06.13.12 | 06:06 am
Press Releases for RGEN
- Repligen Announces Licensing Agreement With Pfizer For Spinal Muscular Atrophy Program - Business Wire 01.03.13 | 07:01 am
- Repligen Reports Third Quarter 2012 Financial Results - Business Wire 11.08.12 | 07:11 am
- Repligen CEO To Present At Upcoming Investor Conferences - Business Wire 11.07.12 | 07:11 am
- Repligen To Report Third Quarter Of 2012 Financial Results - Business Wire 10.26.12 | 07:10 am
- Repligen Appoints Jonathan I. Lieber As CFO - Business Wire 09.21.12 | 06:09 am
- Repligen To Present At Stifel Nicolaus Healthcare Conference 2012 - Business Wire 08.29.12 | 07:08 am
- Repligen Announces Strategic Focus On Bioprocessing Business And Reports Second Quarter 2012 Financial Results - Business Wire 08.02.12 | 07:08 am
- Repligen To Report Second Quarter Of 2012 Financial Results - Business Wire 07.24.12 | 07:07 am
- Ronald L. Chez Files Amended 13D And Letter To The Board - PR Newswire 07.23.12 | 10:07 am
- Repligen To Present At JMP Securities Healthcare Conference 2012 - Business Wire 07.06.12 | 07:07 am
Partner Headlines for RGEN
- Morning Market Movers - Benzinga 09.10.12 | 09:09 am
- Healthcare Insights: J&J Defends, Investors Rattle Repligen, Arena Anxiety Building - Wall St. Cheat Sheet 06.25.12 | 10:06 am
- Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting - Benzinga 04.26.12 | 09:04 am
- 6 Cash Rich Biotech Stocks With Catalysts - Seeking Alpha 04.08.11 | 08:04 am
- Company News for March 08, 2011 - Corporate Summary - Zacks 03.08.11 | 10:03 am
- HEADLINE STOCKS-U.S. small/midcap stocks on the move on May 27 - Reuters 05.27.10 | 10:05 am
- UPDATE 1-FDA, EMA to re-analyze Repligen's late-stage data - Reuters 05.27.10 | 06:05 am
